As more microbiome-based therapies progress through the clinic toward approval for market launch, concerns over the lack of outsourcing capacity for process development and commercial manufacturing high yield LBPs – live biotherapeutic products – are increasing. Arranta Bio has more than a decade of experience in the development and tech transfer of LBPs under GMP…
